CAICaris Life Sciences, Inc.
Is the business good?
Earnings fully cash-backed (1.4×). That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Operating profit is fully backed by cash.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is CAI?
Caris Life Sciences, Inc. earns 14% on the capital it employs against a 9.0% cost of capital, so the business is worth more the bigger it gets.
Return on invested capital · cost of capital 9.0% · 4.7 points above what the capital costs: growth creates value
- Operating margin
- 15%
Operating margin · Biotechnology median −77% · 12 months to Q2 2026
- Cash conversion
- 1.39×
Cash conversion · operating cash flow covers the operating profit after tax
- Share count, year on year
- +336%
Share count, year on year · shareholders own a smaller slice than a year ago
| Year | Operating margin |
|---|---|
| FY2023 | −104% |
| FY2024 | −62% |
| FY2025 | 5.6% |
Details›
- Operating margin12 months to Q2 2026
- 15%
- Net margin12 months to Q2 2026
- 11%
- Free cash flow margin
- 2.4%
- R&D as % of revenue
- 12%
- Revenue, trailing twelve months
- $990M
- Free cash flow, trailing twelve months
- $24M
- Net income, trailing twelve months
- $105M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- 14%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Biotechnology
The closest names by size in the same industry